Depression and Anxiety Disorders
Depression and anxiety are among the world’s leading causes of disease burden, yet our understanding of their pathogenesis remains limited and effective new treatments have proven difficult to develop. Virtually all available medications used to treat depression and anxiety are still based on serendipitous discoveries made more than six decades ago. Despite this frustrating track record for the field, a uniquely broad translational research team at Mount Sinai is now poised to make fundamental advances.
Areas of Research
Genetic and Epigenetic Basis of Depression and Anxiety
We have known for decades that depression and anxiety are highly heritable; however, it has been difficult to identify the specific genes that comprise this risk. Epigenetic regulation, which controls the function of genes, contributes to this difficulty. We are pioneering studies of the genetic and epigenetic causes of depression and anxiety and producing novel information about disease pathogenesis, as well as resistance to these disorders (resilience).
Neural Circuit Basis of Depression and Anxiety
Depression and anxiety are mediated by abnormal functioning of several overlapping neural circuits in the brain. Mount Sinai scientists are studying these abnormal circuits in animal models and in humans using cutting-edge approaches, including optogenetics and brain imaging.
Neuroinflammatory, Metabolic, and Cardiovascular Contributions to Depression and Anxiety
The brain does not function in isolation. It is highly influenced by several other organ systems and, in turn, controls those other organs. This explains why the incidence of depression is very high in a subset of patients with inflammatory disease, obesity, heart disease, and multiple sclerosis, to name a few. Mount Sinai scientists are carrying out groundbreaking research in the role of inflammation, the microbiome, peripheral metabolism, and cardiovascular status in animal models and in humans as a means of developing novel approaches to treatment.
New Treatments for Depression and Anxiety
All of our work in animal models is directed toward clinical advances, in particular, more accurate ways of diagnosing subtypes of depression and anxiety and more effective means of treating them. Mount Sinai scientists, in conjunction with an outstanding team of doctors and other health care providers at the Mount Sinai Health System, are leading the way in new diagnostic and treatment approaches. Learn more. (Link to disease/treatment page within site)
1425 Madison Avenue
New York, NY 10029
Schedule an Appointment
James W. Murrough, MD
1428 Madison Avenue
E Level, Room ABE-39
New York, NY 10029
- Mood and Anxiety Disorders Program
- Patient Psychiatric Services
- Psychiatry FPA
- Clinical Trials for Depression
- Depression Health Library
- Department of Pharmacology and Systems Therapeutics
- Psychiatry Patient Care Mount Sinai Health System
- Neurology Patient Care Mount Sinai Health System
- Department of Neuroscience
- Conte Center